A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer

Exclusion Criteria

• •Participation in other studies involving investigational drug(s) (Phases 1-4) before the current study begins and/or during study participation.
• •Prior irinotecan treatment.
• •Prior radiation to the pelvis or abdomen in the metastatic or locally advanced setting.
• •History of Gilbert's syndrome.
• •Active brain metastases.
• •Deep vein thrombosis in the preceding 2 months.
• •History of interstitial lung disease.
• •RAS (KRAS/NRAS) wild type mCRC not previously treated with an anti-EGFR containing regimen (unless contraindicated or not considered standard practice per clinical site or country guidelines).